BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 25184238)

  • 1. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
    Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
    PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute psychosis related to use of trimethoprim/sulfamethoxazole in the treatment of HIV-infected patients with Pneumocystis jirovecii pneumonia: a multicentre, retrospective study.
    Lee KY; Huang CH; Tang HJ; Yang CJ; Ko WC; Chen YH; Lee YC; Hung CC
    J Antimicrob Chemother; 2012 Nov; 67(11):2749-54. PubMed ID: 22821870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients: A single-centre retrospective study.
    Kato H; Hagihara M; Asai N; Mikamo H; Iwamoto T
    Int J Antimicrob Agents; 2024 May; 63(5):107151. PubMed ID: 38508538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
    Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
    J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with Pneumocystis jirovecii pneumonia.
    Dilworth TJ; Ibrahim OM; Mercier RC
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1246-54. PubMed ID: 25443518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study.
    Nagai T; Matsui H; Fujioka H; Homma Y; Otsuki A; Ito H; Ohmura S; Miyamoto T; Shichi D; Tomohisa W; Otsuka Y; Nakashima K
    Chest; 2024 Jan; 165(1):58-67. PubMed ID: 37574166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.
    Thomas M; Rupali P; Woodhouse A; Ellis-Pegler R
    Scand J Infect Dis; 2009; 41(11-12):862-8. PubMed ID: 19922070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group.
    Walmsley SL; Khorasheh S; Singer J; Djurdjev O
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):498-505. PubMed ID: 9859964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268.
    Para MF; Finkelstein D; Becker S; Dohn M; Walawander A; Black JR
    J Acquir Immune Defic Syndr; 2000 Aug; 24(4):337-43. PubMed ID: 11015150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
    Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
    J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: A cohort study.
    Jacobo-Vargas TB; Báez-Saldaña R; Cruz-Hervert LP; Fortoul TI; Ahumada-Topete VH; Rodríguez-Ganén O; Vega-Barrientos RS
    PLoS One; 2023; 18(5):e0285541. PubMed ID: 37167312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered trimethoprim-sulfamethoxazole ratios for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii dual infections in rat model.
    Brun-Pascaud M; Chau F; Garry L; Farinotti R; Derouin F; Girard PM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):201-7. PubMed ID: 8898664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
    Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
    BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
    Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumocystis carinii pneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection. Northern California Pediatric HIV Consortium.
    Maldonado YA; Araneta RG; Hersh AL
    Pediatr Infect Dis J; 1998 May; 17(5):398-402. PubMed ID: 9613653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
    Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of
    Harada T; Kato R; Sueda Y; Funaki Y; Takata M; Okazaki R; Hasegawa Y; Yamasaki A
    Mod Rheumatol; 2021 May; 31(3):629-635. PubMed ID: 32820678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
    Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
    Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.